The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

FDA approves the biologics license application (BLA) that Dong-A submitted in 2023 for Imuldosa, a biosimilar referencing ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

Targeting T cells with ustekinumab is a potential therapeutic strategy for AAV-GN that merits additional evaluation in ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Fresenius Kabi and Cellular Origins have announced a partnership to advance cell and gene therapy (CGT) by automating ...